Literature DB >> 8206943

Identification of a 3'-->5'-exonuclease that removes cytosine arabinoside monophosphate from 3' termini of DNA.

F W Perrino1, H Miller, K A Ealey.   

Abstract

Cytosine arabinoside monophosphate (araCMP) at the 3' terminus of DNA constitutes a lesion that impedes further synthesis by DNA polymerase alpha (DNA pol alpha). A biochemical assay has been designed to detect 3'-->5'-exonucleases in cell extracts that remove the 3'-araCMP lesion in an oligonucleotide template-primer and permit subsequent extension by DNA pol alpha. The major 3'-->5'-exonuclease activity in human myeloblast extracts has been purified, and gel filtration chromatography of the purified enzyme indicates that the exonuclease has an apparent native molecular mass of 52 kDa. Incubation of the enzyme with a 5'-32P-labeled araCMP template-primer results in exonucleolytic degradation of the primer exclusively in the 3'-->5' direction, demonstrating that the enzyme is a 3'-->5'-exonuclease. The products of the 3'-->5'-exonuclease reaction are 5'-mononucleotides. The apparent rate of araCMP removal by the exonuclease is approximately the same as the rate of deoxynucleoside monophosphate (dNMP) removal. Furthermore, the apparent rates of 3'-terminal excision are approximately the same whether the oligomer is hybridized to a complementary oligonucleotide, or not, indicating that the enzyme has both single- and double-stranded 3'-->5'-exonuclease activity. The enzyme does not possess 5'-->3'-exonuclease activity, nor is it associated with DNA polymerase activity. In addition, the enzyme does not cleave 3'-phosphoryl-terminated DNA, and it does not cleave RNA. The enzymatic characteristics of the isolated 3'-->5'-exonuclease indicate that it is distinct from previously identified mammalian deoxyribonucleases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8206943

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  The TREX1 exonuclease R114H mutation in Aicardi-Goutières syndrome and lupus reveals dimeric structure requirements for DNA degradation activity.

Authors:  Clinton D Orebaugh; Jason M Fye; Scott Harvey; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2011-09-21       Impact factor: 5.157

2.  WRN exonuclease activity is blocked by DNA termini harboring 3' obstructive groups.

Authors:  Jeanine A Harrigan; Jinshui Fan; Jamil Momand; Fred W Perrino; Vilhelm A Bohr; David M Wilson
Journal:  Mech Ageing Dev       Date:  2006-12-20       Impact factor: 5.432

3.  The TREX1 double-stranded DNA degradation activity is defective in dominant mutations associated with autoimmune disease.

Authors:  Duane A Lehtinen; Scott Harvey; Matthew J Mulcahy; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2008-09-18       Impact factor: 5.157

4.  Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.

Authors:  Jessica L Grieves; Jason M Fye; Scott Harvey; Jason M Grayson; Thomas Hollis; Fred W Perrino
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-06       Impact factor: 11.205

5.  Measuring TREX1 and TREX2 exonuclease activities.

Authors:  Wayne O Hemphill; Fred W Perrino
Journal:  Methods Enzymol       Date:  2019-06-08       Impact factor: 1.600

6.  The Arg-62 residues of the TREX1 exonuclease act across the dimer interface contributing to catalysis in the opposing protomers.

Authors:  Jason M Fye; Stephanie R Coffin; Clinton D Orebaugh; Thomas Hollis; Fred W Perrino
Journal:  J Biol Chem       Date:  2014-03-09       Impact factor: 5.157

7.  Gene-targeted mice lacking the Trex1 (DNase III) 3'-->5' DNA exonuclease develop inflammatory myocarditis.

Authors:  Masashi Morita; Gordon Stamp; Peter Robins; Anna Dulic; Ian Rosewell; Geza Hrivnak; Graham Daly; Tomas Lindahl; Deborah E Barnes
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  Structural and biochemical studies of TREX1 inhibition by metals. Identification of a new active histidine conserved in DEDDh exonucleases.

Authors:  Marina Brucet; Jordi Querol-Audí; Kamila Bertlik; Jorge Lloberas; Ignacio Fita; Antonio Celada
Journal:  Protein Sci       Date:  2008-09-09       Impact factor: 6.725

9.  TREX1 acts in degrading damaged DNA from drug-treated tumor cells.

Authors:  Chuan-Jen Wang; Wing Lam; Scott Bussom; Hua-Mei Chang; Yung-Chi Cheng
Journal:  DNA Repair (Amst)       Date:  2009-07-18

10.  The anti-human immunodeficiency virus agent 3'-fluorothymidine induces DNA damage and apoptosis in human lymphoblastoid cells.

Authors:  R Sundseth; S S Joyner; J T Moore; R E Dornsife; I K Dev
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.